1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61A79326917A80B980025876C004CE207
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-managing-hostile-stakeholders-during-launch-breakthrough-new-medicine-using-science-defuse-hostility-working-with-pricing-opposition-groups?opendocument
18
19opendocument
203.89.204.127
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Using Science to Defuse Hostility and Working with Pricing Opposition Groups

ID: 5701


Features:

27 Info Graphics

60+ Metrics

25 Narratives


Pages/Slides: 35


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Using Science to Defuse Hostility and Working with Pricing Opposition Groups”

STUDY OVERVIEW

The stakes are high for pharma teams preparing to launch a new breakthrough medicine. While the drug holds potential to achieve blockbuster status owing to factors such as fulfilling an unmet need or first-mover advantage, there is a significant probability of garnering hostile responses from key stakeholders in case of an associated stigma or controversy around the product.

Consequently, many pharma companies are developing rapid response teams to map and engage the full range of hostile stakeholder groups.

Best Practices, LLC engaged senior launch leadership from pharma companies and conducted extensive secondary research to highlight effective strategies for managing hostile stakeholders during the launch of a breakthrough new medicine.

The study delves into key aspects including: mapping and engaging hostile stakeholders; using science to defuse hostility and build the value story, and working with pricing opposition groups during product launch.

KEY TOPICS

  • Mapping & Managing Hostile Groups Across the Market Landscape
  • Using Science to Communicate Data to Defuse Hostility and Build the Value Story
  • Working with Pricing Opposition Groups

SAMPLE KEY FINDINGS

  • No Go Zones: Avoid engaging advocacy groups that provide services misaligned with your product but monitor them for potential conflicts.
  • Working with Pricing Opposition Groups: Employ a flexible discount strategy. Rather than lowering price, negotiate preferred discounts for public payers and key PBMs like Express Scripts.

METHODOLOGY

Best Practices, LLC engaged front-line executives at 11 companies across 9 therapeutic areas to conduct this analysis on hostile stakeholder management. Extensive secondary research was also conducted to identify industry best practices.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Bayer; Boehringer Ingelheim; Eli Lilly and Company; Gilead Sciences; GlaxoSmithKline ; Johnson & Johnson; Merck; Pfizer; Roche; Sprout Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.